MX2018005588A - Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno. - Google Patents

Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.

Info

Publication number
MX2018005588A
MX2018005588A MX2018005588A MX2018005588A MX2018005588A MX 2018005588 A MX2018005588 A MX 2018005588A MX 2018005588 A MX2018005588 A MX 2018005588A MX 2018005588 A MX2018005588 A MX 2018005588A MX 2018005588 A MX2018005588 A MX 2018005588A
Authority
MX
Mexico
Prior art keywords
plasminogen
deficiency
subject
replacement therapy
deficient subject
Prior art date
Application number
MX2018005588A
Other languages
English (en)
Spanish (es)
Inventor
Laurin Pierre
Robitaille Martin
Plum Stacy
Thibaudeau Karen
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of MX2018005588A publication Critical patent/MX2018005588A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2018005588A 2015-11-03 2016-11-03 Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno. MX2018005588A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (1)

Publication Number Publication Date
MX2018005588A true MX2018005588A (es) 2018-11-09

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005588A MX2018005588A (es) 2015-11-03 2016-11-03 Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno.

Country Status (25)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
DK (1) DK3370760T3 (enExample)
ES (1) ES3055824T3 (enExample)
FI (1) FI3370760T3 (enExample)
HR (1) HRP20251512T1 (enExample)
IL (1) IL258913B (enExample)
LT (1) LT3370760T (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
PL (1) PL3370760T3 (enExample)
PT (1) PT3370760T (enExample)
RS (1) RS67519B1 (enExample)
RU (1) RU2736831C2 (enExample)
SI (1) SI3370760T1 (enExample)
SM (1) SMT202500451T1 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
WO2017101866A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
WO2017101871A1 (zh) * 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
US12011455B2 (en) 2016-03-17 2024-06-18 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
TWI677348B (zh) * 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
TWI750189B (zh) * 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
JP7213552B2 (ja) * 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
WO2018107701A1 (zh) * 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113597313A (zh) * 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
WO1994001128A1 (en) * 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
EP0682700A4 (en) * 1993-02-05 1997-05-28 Vascular Lab USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE.
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
CA2662101C (en) * 2006-08-28 2015-07-07 Omnio Healer Ab Candidates against infection
AU2007290882B2 (en) * 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
NZ597452A (en) * 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
KR20130100290A (ko) * 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
PY1577621A (es) * 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
JP2019500426A (ja) * 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法

Also Published As

Publication number Publication date
US11291711B2 (en) 2022-04-05
TW201722463A (zh) 2017-07-01
US20190231854A1 (en) 2019-08-01
IL258913B (en) 2021-12-01
NZ742657A (en) 2024-04-26
TWI801331B (zh) 2023-05-11
AU2016347863A1 (en) 2018-06-07
SMT202500451T1 (it) 2026-01-12
RU2736831C2 (ru) 2020-11-20
CN108289935A (zh) 2018-07-17
CA3002915A1 (en) 2017-05-11
PL3370760T3 (pl) 2026-03-23
RU2018120182A3 (enExample) 2020-04-27
JP6878423B2 (ja) 2021-05-26
AU2016347863B2 (en) 2023-11-09
EP3370760A4 (en) 2019-06-26
ZA201802820B (en) 2019-07-31
MY199581A (en) 2023-11-07
BR112018008965A2 (pt) 2018-11-21
KR102821400B1 (ko) 2025-06-18
KR20180083348A (ko) 2018-07-20
DK3370760T3 (da) 2025-12-22
FI3370760T3 (fi) 2025-12-05
PT3370760T (pt) 2025-12-03
EP3370760B1 (en) 2025-10-01
BR112018008965A8 (pt) 2019-02-26
RU2018120182A (ru) 2019-12-04
SI3370760T1 (sl) 2026-02-27
IL258913A (en) 2018-06-28
CA3002915C (en) 2024-01-16
JP2018533589A (ja) 2018-11-15
LT3370760T (lt) 2025-12-29
ES3055824T3 (en) 2026-02-16
RS67519B1 (sr) 2025-12-31
HRP20251512T1 (hr) 2026-06-05
EP3370760A1 (en) 2018-09-12
WO2017077380A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
MY199581A (en) Plasminogen replacement therapy for plasminogen-deficiency
MX2021009830A (es) Metodos para el tratamiento de trastornos del movimiento involuntario anormal.
MY187486A (en) Cysteine protease
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
ZA201705113B (en) Cysteine protease
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
GB2541571A (en) Pharmaceutical compositions
NZ750174A (en) Somatostatin modulators and uses thereof
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
SG10201808063PA (en) Compositions for modulating ataxin 2 expression
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2017017171A (es) Compuestos terapeuticos y composiciones para el tratamiento de trastornos sociales y trastornos de uso de sustancias.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
MX375737B (es) Imidazopirazinonas como inhibidores de pde1.
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
PH12020551179A1 (en) Methods for treating mitochondrial disorder
TW201613639A (en) Methods for treating cardiovascular diseases
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
EP3725320C0 (en) COMPOSITION COMPRISING A STRAIN OF AGATHOBACULUM SP. AS AN ACTIVE INGREDIENT FOR THE PREVENTION, MITIGATION OR TREATMENT OF AN AUTISM SPECTRUM DISORDER
PH12017501918A1 (en) Multi-peptide composition
WO2018089204A3 (en) Combination therapies for treating bipolar disorder, and methods for using the same
MX2017013669A (es) Composiciones para el tramiento del cancer.
UA98863U (en) Method for treating endometrial hyperplasia of patients of reproductive age